New biomarkers in brain trauma.

Clin Chim Acta

Department of Biotechnology, Indian Institute of Technology (IIT) Hyderabad, Sangareddy 502285, Telangana, India. Electronic address:

Published: December 2018

Brain-specific biomolecules are being increasingly investigated as a viable alternative to the clinical scores and radiological features, on which we still rely upon for stratification, therapy and predicting outcome in traumatic brain injury (TBI). TBI generally leads to release of various chemical compound within the cerebrospinal fluid (CSF) or blood depending on the severity of injury, which were studied variedly in last decades. However, most of these compounds being non-specific to brain, their applicability was challenged further. This review encompasses the novel and promising biomarkers being studied in the present decade, with encouraging results in laboratory and animal or human models.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2018.10.025DOI Listing

Publication Analysis

Top Keywords

biomarkers brain
4
brain trauma
4
trauma brain-specific
4
brain-specific biomolecules
4
biomolecules increasingly
4
increasingly investigated
4
investigated viable
4
viable alternative
4
alternative clinical
4
clinical scores
4

Similar Publications

Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD). Brain polyglucosan bodies (PBs) cause fatal neurodegenerative diseases including Lafora disease and adult polyglucosan body disease (ABPD), for which treatments, biomarkers, and good understanding of their pathogenesis are currently missing. Mutations in the genes for the phosphatase laforin or the E3 ubiquitin ligase malin can cause LD.

View Article and Find Full Text PDF

A comprehensive genome-wide association study (GWAS) has validated the identification of the Plexin-A 4 (PLXNA4) gene as a novel susceptibility factor for Alzheimer's disease (AD). Nonetheless, the precise role of PLXNA4 gene polymorphisms in the pathophysiology of AD remains to be established. Consequently, this study is aimed at exploring the relationship between PLXNA4 gene polymorphisms and neuroimaging phenotypes intimately linked to AD.

View Article and Find Full Text PDF

Titin fragment is a sensitive biomarker in Duchenne muscular dystrophy model mice carrying full-length human dystrophin gene on human artificial chromosome.

Sci Rep

January 2025

Department of Chromosome Biomedical Engineering, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683‑8503, Japan.

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations of the dystrophin gene, which spans 2.4 Mb on the X chromosome. Creatine kinase (CK) activity in blood and titin fragment levels in urine have been identified as biomarkers in DMD to monitor disease progression and evaluate therapeutic intervention.

View Article and Find Full Text PDF

GNG2 inhibits brain metastases from colorectal cancer via PI3K/AKT/mTOR signaling pathway.

Sci Rep

January 2025

Department of Gastrointestinal Surgery, Third Xiangya Hospital, Central South University, Changsha, 410006, China.

G-protein gamma subunit 2 (GNG2) plays a vital role in various cellular processes, yet its specific function in colorectal cancer (CRC), particularly in highly invasive cases and brain metastasis, remains unclear. This study identifies GNG2 as a key regulator in metastatic colorectal cancer (mCRC) through bioinformatics analysis and experimental validation. Functional enrichment analyses reveal that GNG2 is related to the PI3K/AKT/mTOR signaling pathway and cell cycle regulation.

View Article and Find Full Text PDF

Anti-amyloid therapy and cerebral blood flow changes on Magnetic Resonance Imaging: a potential longitudinal biomarker of treatment response?

AJNR Am J Neuroradiol

January 2025

From the Department of Department of Radiology, Brain Health Imaging Institute (A.R-F, J.I, S.P, M.d, G.C.C) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA; the Department of Neurology (A.R-F), Pontificia Universidad Javeriana, Bogota, Colombia; the Department of Radiology, Division of Molecular Imaging and Therapeutics (A.R-F, J.I) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA; the Department of Neurology (D.Z, MM, L.R, A.S.N) Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA.

Amyloid-targeting therapy has recently become widely available in the U.S. for the treatment of patients with symptomatic mild Alzheimer's disease (AD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!